To analysts, the drug’s apparent safety and effects on both triglyceride levels and pancreatitis cases should make it competitive with a rival Ionis therapy.

To analysts, the drug’s apparent safety and effects on both triglyceride levels and pancreatitis cases should make it competitive with a rival Ionis therapy.

Less than a month after Ionis Pharmaceuticals scored an FDA expansion for Tryngolza to become t | Less than a month after Ionis scored an FDA expansion for Tryngolza to become the…